---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-22-000022"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2022-07-11T23:59:59+00:00"
generated_at: "2026-06-24T17:54:27.694329+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vertex acquires ViaCyte for $320M cash to accelerate T1D stem cell therapy VX-880

## Summary
- Vertex to acquire ViaCyte for $320 million in cash; ViaCyte becomes wholly owned subsidiary.
- Goal is to accelerate development of VX-880, Vertex's investigational stem cell-derived islet therapy for T1D.
- ViaCyte brings complementary tools: stem cell lines, IP, GMP manufacturing, and hypoimmune assets via CRISPR collaboration.
- Acquisition expected to close later this year, subject to HSR waiting period and other customary conditions.

## SEC filing metadata
- accession: 0000875320-22-000022
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2022-07-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532022000022/0000875320-22-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532022000022/vrtx-20220709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-22-000022
- JSON: https://secwatch.observer/filing/0000875320-22-000022.json
- Plain text: https://secwatch.observer/filing/0000875320-22-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.